#1Science 37 TECHNOLOGIES Ⓡ The Clinical Trial Operating System. Science 37#2Disclaimers and Other Important Information This presentation (this "Presentation") is provided for informational purposes only and has been prepared to assist interested parties in making their own evaluation with respect to a potential business combination between Science 37, Inc. ("Science 37") and LifeSci Acquisition II Corp. ("LSAQ") and related transactions (the "Potential Business Combination") and for no other purpose. By reviewing or reading this Presentation, you will be deemed to have agreed to the obligations and restrictions set out below. Without the express prior written consent of LSAQ and Science 37, this Presentation and any information contained within it may not be (i) reproduced (in whole or in part), (ii) copied at any time, (iii) used for any purpose other than your evaluation of Science 37 and the Potential Business Combination or (iv) provided to any other person, except your employees and advisors with a need to know who are advised of the confidentiality of the information. This Presentation supersedes and replaces all previous oral or written communications between the parties hereto relating to the subject matter hereof. This Presentation and any oral statements made in connection with this Presentation do not constitute an offer to sell, or a solicitation of an offer to buy, or a recommendation to purchase, any securities in any jurisdiction, or the solicitation of any proxy, vote, consent or approval in any jurisdiction in connection with the Potential Business Combination or any related transactions, nor shall there be any sale, issuance or transfer of any securities in any jurisdiction where, or to any person to whom, such offer, solicitation or sale may be unlawful under the laws of such jurisdiction. This Presentation does not constitute either advice or a recommendation regarding any securities. Any offer to sell securities will be made only pursuant to a definitive subscription agreement and will be made in reliance on an exemption from registration under the Securities Act of 1933, as amended, for offers and sales of securities that do not involve a public offering. LSAQ and Science 37 reserve the right to withdraw or amend for any reason any offering and to reject any subscription agreement for any reason. The communication of this Presentation is restricted by law; it is not intended for distribution to, or use by any person in, any jurisdiction where such distribution or use would be contrary to local law or regulation. No representations or warranties, express or implied are given in, or in respect of, this Presentation. To the fullest extent permitted by law, in no circumstances will LSAQ, Science 37 or any of their respective subsidiaries, stockholders, affiliates, representatives, partners, directors, officers, employees, advisers or agents be responsible or liable for any direct, indirect or consequential loss or loss of profit arising from the use of this Presentation, its contents (including the internal economic models), its omissions, reliance on the information contained within it, or on opinions communicated in relation thereto or otherwise arising in connection therewith. Industry and market data used in this Presentation have been obtained from third-party industry publications and sources as well as from research reports prepared for other purposes. Neither LSAQ nor Science 37 has independently verified the data obtained from these sources and cannot assure you of the data's accuracy or completeness. This data is subject to change. Recipients of this Presentation are not to construe its contents, or any prior or subsequent communications from or with LSAQ, Science 37 or their respective representatives as investment, legal or tax advice. In addition, this Presentation does not purport to be all-inclusive or to contain all of the information that may be required to make a full analysis of Science 37 or the Potential Business Combination. Recipients of this Presentation should each make their own evaluation of Science 37 and the Potential Business Combination and of the relevance and adequacy of the information and should make such other investigations as they deem necessary. Forward-Looking Statements This Presentation contains certain forward-looking statements within the meaning of the federal securities laws with respect to the proposed transaction between Science 37 and LS including statements regarding the benefits of the trans ction, the anticipated timing of the transaction, the services offered by Science 37 and the markets in which it operates, and Science 37's projected future results. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result" and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this Presentation, including but not limited to: (i) the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect the price of LSAQ's securities, (ii) the risk that the transaction may not be completed by LSAQ's business combination deadline and the potential failure to obtain an extension of the business combination deadline if sought by LSAQ, (iii) the failure to satisfy the conditions to the consummation of the transaction, including the adoption of the agreement and plan of merger by the stockholders of LSAQ and Science 37, the satisfaction of the minimum trust account amount following redemptions by LSAQ's public stockholders and the receipt of certain governmental and regulatory approvals, (iv) the lack of a third party valuation in determining whether or not to pursue the proposed transaction, (v) the occurrence of any event, change or other circumstance that could give rise to the termination of the agreement and plan of merger, (vi) the effect of the announcement or pendency of the transaction on Science 37's business relationships, performance, and business generally, (vii) risks that the proposed transaction disrupts current plans of Science 37 and potential difficulties in Science 37 employee retention as a result of the proposed transaction, (viii) the outcome of any legal proceedings that may be instituted against Science 37 or against LSAQ related to the agreement and plan of merger or the proposed transaction, (ix) the ability to maintain the listing of LSAQ's securities on the Nasdaq Capital Market ("Nasdaq"), (x) the price of LSAQ's securities may be volatile due to a variety of factors, including changes in the competitive and highly regulated industries in which Science 37 plans to operate, variations in performance across competitors, changes in laws and regulations affecting Science 37's business and changes in the combined capital structure (xi) the ability to implement business plans, forecasts, and other expectations after the completion of the proposed transaction, and identify and realize additional opportunities, and (xii) the potential adverse effects of the ongoing global COVID-19 pandemic. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of LSAQ's Registration Statement on Form S-1, the registration statement on Form S-4 and proxy statement/consent solicitation statement/prospectus described below and other documents filed by LSAQ from time to time with the U.S. Securities and Exchange Commission (the "SEC"). These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Science 37 and LSAQ assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Neither Science 37 nor LSAQ gives any assurance that either Science 37 or LSAQ will achieve its expectations. Science 37 2#3Disclaimers and Other Important Information (continued) Use of Projections This Presentation contains projected financial information with respect to Science 37. Such projected financial information constitutes forward-looking information and is for illustrative purposes only and should not be relied upon as necessarily being indicative of future results. The assumptions and estimates underlying such financial forecast information are inherently uncertain and are subject to a wide variety of significant business, economic, competitive and other risks and uncertainties. See "Forward-Looking Statements" above. Actual results may differ materially from the results contemplated by the financial forecast information contained in this Presentation, and the inclusion of such information in this Presentation should not be regarded as a representation by any person that the results reflected in such forecasts will be achieved. Financial Information; Non-GAAP Financial Terms The financial information and data contained this Presentation is unaudited and does not conform to Regulation S-X promulgated by the SEC. Accordingly, such information and data may not be included in, may be adjusted in, or may be presented differently in, any proxy statement/consent solicitation statement/prospectus or registration statement or other report or document to be filed or furnished by LSAQ with the SEC. Furthermore, some of the projected financial information and data contained in this Presentation, such as Adjusted EBITDA (and related measures), has not been prepared in accordance with United States generally accepted accounting principles ("GAAP"). Science 37 and LSAQ believe these non-GAAP measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to Science 37's financial condition and results of operations. Science 37's management uses these non-GAAP measures for trend analyses and for budgeting and planning purposes. Science 37 and LSAQ believe that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating projected operating results and trends in and in comparing Science 37's financial measures with other similar companies, many of which present similar non-GAAP financial measures to investors. Management of Science 37 does not consider these non- GAAP measures in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of these non-GAAP financial measures is that they exclude significant expenses and income that are required by GAAP to be recorded in Science 37's financial statements. In addition, they are subject to inherent limitations as they reflect the exercise of judgments by management about which expense and income are excluded or included in determining these non-GAAP financial measures. You should review Science 37's audited financial statements, which will be presented in LSAQ's proxy statement/consent solicitation statement/prospectus to be filed with the SEC, and not rely on any single financial measure to evaluate Science 37's business. A reconciliation of non-GAAP financial measures in this Presentation to the most directly comparable GAAP financial measures is not included, because, without unreasonable effort, Science 37 is unable to predict with reasonable certainty the amount or timing of non-GAAP adjustments that are used to calculate these Non-GAAP financial measures. Trademarks This Presentation contains trademarks, service marks, trade names, and copyrights of Science 37, LSAQ and other companies, which are the property of their respective owners. Additional Information and Where to Find It This document relates to a proposed transaction between Science 37 and LSAQ. This document does not constitute an offer to sell or exchange, or the solicitation of an offer to buy or exchange, any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, sale or exchange would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. LSAQ intends to file a registration statement on Form S-4 that will include a proxy statement of LSAQ, a consent solicitation statement of Science 37 and a prospectus of LSAQ. The proxy statement/consent solicitation statement/prospectus will be sent to all LSAQ and Science 37 stockholders. LSAQ also will file other documents regarding the proposed transaction with the SEC. Before making any voting decision, investors and security holders of LSAQ and Science 37 are urged to read the registration statement, the proxy statement/consent solicitation statement/prospectus and all other relevant documents filed or that will be filed with the SEC in connection with the proposed transaction as they become available because they will contain important information about the proposed transaction. Investors and security holders will be able to obtain free copies of the proxy statement/consent solicitation statement/prospectus and all other relevant documents filed or that will be filed with the SEC by LSAQ through the website maintained by the SEC at www.sec.gov. In addition, the documents filed by LSAQ may be obtained free of charge from LSAQ's website at www.lifesciacquisition.com/spac-2/ or by written request to LSAQ at LifeSci Acquisition II Corp., 250 West 55th Street, Suite 34, New York, NY 10019. Participants in Solicitation LSAQ and Science 37 and their respective directors and officers may be deemed to be participants in the solicitation of proxies from LSAQ's stockholders in connection with the proposed transaction. Information about LSAQ's directors and executive officers and their ownership of LSAQ's securities is set forth in LSAQ's filings with the SEC, including LSAQ's Registration Statement on Form S-1, which was filed with the SEC on October 14, 2020. To the extent that holdings of LSAQ's securities have changed since the amounts printed in LSAQ's Registration Statement on Form S-1, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC. Additional information regarding the interests of those persons and other persons who may be deemed participants in the proposed transaction may be obtained by reading the proxy statement/prospectus regarding the proposed transaction when it becomes available. You may obtain free copies of these documents as described in the preceding paragraph. Science 37#4Risk Factors Risks related to our limited operating history and early stage of growth 1. We have a limited operating history on which to assess the prospects for our business and we have incurred losses since inception. We anticipate that we will continue to incur significant losses for at least the next several years. 2. We have incurred significant losses since inception. As such, you cannot rely upon our historical operating performance to make an investment or voting decision regarding the company. We have experienced rapid growth and expect to invest in growth for the foreseeable future. If we fail to manage growth effectively, our business, operating results and financial condition would be adversely affected. We may need to raise additional funding to expand the commercialization of our products and services and to expand our research and development efforts. This additional financing may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product commercialization or development efforts or other operations. 3. 4. 5. 6. 7. A failure to identify and successfully close and integrate strategic acquisition targets could adversely impact our ongoing business and financial results. Unfavorable general economic conditions could negatively affect our business, results of operations and financial condition. Our actual operating results may differ significantly from guidance provided by our management. Risks related to our business and operations 1. Our forecasts and projections are based upon assumptions, analyses and internal estimates developed by our management. If these assumptions, analyses or estimates prove to be incorrect or inaccurate, our actual operating results may differ materially from those forecasted or projected. The potential loss, delay, or non-renewal of our contracts or any delay in our clients' clinical trials or non-payment by our clients for services that we have performed, could negatively affect our business, results of operations and financial results. Our backlog may not convert to revenue at the historical conversion rate. If we are unable to successfully develop and market new services or enter new markets, our growth, results of operations or financial condition could be adversely affected. Our relationships with existing or potential clients who are in competition with each other may adversely impact the degree to which other clients or potential clients use our services, which may adversely affect our results of operations. 2. 3. 4. 5. 6. If we are unable to attract suitable investigators and patients for our clinical trials, our clinical development business may suffer. 7. We rely on third parties for important products and services. 8. If we lose the services of key personnel or are unable to recruit and retain experienced personnel, our business could be adversely affected. 9. Failure to meet productivity objectives under our internal business transformation initiatives could adversely impact our competitiveness and harm our operating results. 10. Our insurance may not cover all of our indemnification obligations and other liabilities associated with our operations. 11. We derive a significant percentage of our revenues from a concentrated group of clients and the loss of one or more major clients could materially and adversely affect our business, results of operations or financial condition. 12. Current and future litigation against us, which may arise in the ordinary course of our business, could be costly and time consuming to defend. 13. We expect to incur increased costs and obligations as a result of being a public company. 14. While we to date have not made material acquisitions, should we pursue acquisitions in the future, we would be subject to risks associated with acquisitions. Science 37 4#5Risk Factors (continued) Risks related to the general economic and financial market conditions and the industries in which we operate 1. The effects of the COVID-19 pandemic could adversely affect our business, results of operations, and financial condition. 2. We depend entirely on the clinical trial market, and a downturn in this market could cause our revenues to decrease. 3. 4. Risks related to technology and intellectual property 2. 1. Our business depends on the continued effectiveness and availability of our information systems, including the information systems we use to provide our services to our clients, and failures of these systems may materially limit our operations. A failure or breach of our IT systems or technology could result in sensitive client information being compromised or otherwise significantly disrupt our business operations, which would negatively materially affect our reputation and/or results of operations. 3. 4. 5. 6. 7. 8. Consolidation among our clients could cause us to lose clients, decrease the market for our products and result in a reduction of our revenues. Our estimate of the market size for our services may prove to be inaccurate, and even if the market size is accurate, we cannot assure you that our business will serve a significant portion of the market. 3. 4. 5. 6. 7. Computer malware, viruses, ransomware, hacking, phishing attacks and other network disruptions could result in security and privacy breaches and interruption in service, which would harm our business. Our services are subject to evolving industry standards and rapid technological changes. If we do not keep pace with rapid technological changes, our services may become less competitive or obsolete, which could have a material adverse effect on our business, results of operations and financial condition. We rely on third parties to provide certain data and other information to us. Our suppliers or providers might increase our cost to obtain, restrict our use of, or refuse to license data, which could lead to our inability to access certain data or provide certain services and, as a result, materially and adversely affect our operating results and financial condition. Risks related to political, legal and regulatory environment 1. We may face political, legal and compliance, operational, regulatory, economic and other risks associated with the international expansion of our operations that we do not currently face or that are more significant than in our domestic operations. Due to the global nature of our business, we may be exposed to liabilities under anti-corruption laws, including the United States Foreign Corrupt Practices Act, the United Kingdom Bribery Act and various international anti-corruption laws, and any allegation or determination that we violated these laws could have a material adverse effect on our business. 2. Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business. If we fail to comply with certain healthcare laws, including fraud and abuse laws, we could face substantial penalties and our business, results of operations, financial condition, and prospects could be adversely affected. Extensive governmental regulation of the clinical trial process and our products and services could require significant compliance costs and have a material adverse effect on the demand for our solutions. We rely on third parties for important products, services and licenses to certain technology and intellectual property rights and we might not be able to continue to obtain such products, services and licenses. We have only a limited ability to protect our intellectual property rights, both domestically and internationally, and these rights are important to our success. Our cloud-based solutions and services utilize open source software, and any failure to comply with the terms of one or more of these open source licenses could adversely affect our business. Data protection laws and regulations may limit the use of our platform and give rise to operational interruption, liabilities, and reputational harm, which could have a materially adverse impact on our business. The enactment of legislation implementing changes in the U.S. taxation of international business activities, the adoption of other tax reform policies or changes in tax legislation or policies in jurisdictions outside of the United States could materially impact our results of operations and financial condition. Science 37 5#6Risk Factors (continued) Risk related to our common stock 1. Future sales of our stock in the public market could cause the market price of our stock to decrease significantly. If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, our stockholders could lose confidence in our financial and other public reporting, which would harm its business and the trading price of our common stock. Since we have no current plans to pay regular cash dividends on our common stock, stockholders may not receive any return on investment unless they sell their common stock for a price greater than that which they paid for it. If securities analysts or industry analysts do not publish reports about our business or if they downgrade our stock or our sector, our stock price and trading volumes could decline. 5. Delaware law and provisions in our certificate of incorporation and bylaws could make a takeover proposal more difficult. 6. Our bylaws designate the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings and the federal district courts as the sole and exclusive forum for other types of actions and proceedings, in each case, that may be initiated by our stockholders, which could limit our stockholders' ability to obtain what such stockholders believe to be a favorable judicial forum for disputes with the company or our directors, officers or other employees. 2. 3. 4. Science 37#7Today's Presenters Science 37 David Coman CEO Science 37 80 Mike Zaranek CFO Science 37 Dave Dobkin CFO Life Sci Acquisition II#8Transaction Overview. Science 37 has agreed to key terms of a potential business combination with LifeSci Acquisition II Corp. (LifeSci) Transaction Structure: Use of Proceeds: Valuation: Timeline: Science 37 $80.1M cash in trust(a); $200.0M PIPE proceeds Selling shareholders of the company to receive newly issued shares of SPAC common stock at $10.00 per share and an additional 12.5 million shares subject to a price-based earnout(b) The company intends to use the net proceeds from the transaction for geographic expansion, to expand its tech platform to further service pharma and to pursue M&A opportunities $1,300 pro forma equity value; $1,050 pro forma fully-diluted TEV with no debt outstanding at closing Proposed transaction announcement date during the week of May 3rd (a) Assumes no redemption from LifeSci's existing public shareholders. (b) 5 million earnout shares at $15.00 and 7.5 million earnout shares at $20.00 (for 20 trading days of any consecutive 30 trading day period following closing) 8#9Transaction Detail. Sources, Uses. and Pro Forma Cap Table SOURCES ($M) Common Stock Issued to S37 Cash Held in Trust(a) PIPE Total Sources ($M, %) PRO FORMA VALUATION PF Shares LSAQ Sponsor Shares Public Shareholders S37 Roll-Over PIPE Pro Forma Shares Outstanding (b) Share Price Pro Forma Shares Outstanding Total Equity Value ($10 per share) Plus: Debt Less: Cash Pro Forma Fully-Diluted TEV 2023E Revenue EV / 2023E Revenue Science 37 2.0 8.0 100.0 20.0 130.0 $1,000 80 200 $1,280 Ownership 1.5% 6.2% 76.9% 15.4% 100.0% $10.00 130.0 $1,300.1 0 (250) $1,050.0 $182.50 5.8x ($M) Common Stock Issued Payment of Transaction Expenses Cash to Balance Sheet Total Uses ILLUSTRATIVE PRO FORMA OWNERSHIP(b) ■ PIPE ■LSAQ Sponsor Shares ■ Public Shareholders USES ■ S37 Roll-Over S37 Roll-Over, 76.9% $1,000 30 250 $1,280 PIPE, 15.4% LSAQ Sponsor Shares, 1.5% Public Shareholders, 6.2% Note: deal is on a cash free, debt free basis. (a) Assumes no redemption from LifeSci's existing public shareholders. (b) Share count excludes i) 3.146M private placement warrants (strike price of $11.50) that are expected to be converted into share of common stock at the closing and ii) 12.5M of seller earnout shares (5M shares vesting at $15.00/share and 7.5M vesting at $20.00/share).#10Highly Experienced in Technology and Science. BACO Steven Geffon Chief Commercial Officer David Coman Chief Executive Officer Science 37 Jonathan Cotliar Chief Medical Officer O QUINTILES ERT Harbor-UCLA MEDICAL CENTER Mike Zaranek Chief Financial Officer Chris Ceppi Chief Product Officer IQVIA EY Mucker Capital PING Drew Bustos Chief Strategy and Marketing Officer medrio ERT IQVIA ERT Darcy Forman Chief Delivery Officer Laura Podolsky General Counsel FIRMA CLINICAL RESEARCH Jim Young Chief HR Officer THEODORA ORINGHER CXIGLALAK Anita Modi VP Business Transformation Sp Clinipace CLINICAL RESEARCH WebMD aptuit athenahealth 10#11Investing in our Foundation of Success. Rob Faulkner Redmile Group Chairman Investors: Science 37 John Hubbard SIGNANT HEALTH Pfizer > BIOCLINICA RESEARCH Independent LUX LIFESCI VENTURE PARTNERS Adam Goulburn LUX 191055 Bhooshi Desilva PPD GLYNN CAPITAL.. PPD INVESTMENTS, LLC Redmile Group SANOFI VENTURES Neil Tiwari NOVARTIS AMGEN G/ Scott Jordan GLYNN CAPITAL. MANAGEMENT Observer & NOVARTIS MUBADALA 11#12Science 37 Investment Highlights. Disrupting the $60b Clinical Trial Industry Science 37 $3 § X X 1 ■ ■ ■ Category-Defining Clinical Trial Operating System Unifying technology platform to enable workflow, evidence generation and data harmonization On-demand telemedicine investigators and gig-economy nursing for home visits Integrations into networks (EHR and EDC) and connected devices to expedite trial operations Strong Financial Performance $444M net bookings in 2025 expected to increase from $119M in 2021 $362M revenue in 2025 expected to increase from $52M in 2021 Gross profit margin expected to increase to 55% in 2025 I I ■ ■ ■ ■ Significant Growth Opportunities Ahead Model expansion: commercial, geographic, technology Expanded offerings: rapidly growing adjacencies Potential M&A opportunities Up to 15x faster than traditional clinical trials Up to 28x greater patient/participant retention Up to 3x more diverse participants ■ 12#13Clinical Trial Model is Ripe for Disruption. Traditional Site-Centric Model is Not Working... Clinical Trial model has Sponsor not changed in >90 years ■ ■ Multiple legacy technologies with technical debt 1920s Poorly integrated systems lead to redundant resources and duplicate work Redundant processes to fully leverage new technologies and workflow Traditional Clinical Trials 2010s Science 37 Site Coordinator Investigator Nurse Contract Research Associates Patients DIDI of Declining Performance 1 80%* TRIALS EXPERIENCE DELAYS N 2 20%* AVG. PATIENT DROPOUT RATE 3 14%* MINORITIES REPRESENTED 4 7-13 YEARS TO LAUNCH A DRUG 1. Source: Article from Drug Development & Drug delivery https://drug-dev.com/cost-of-disrupted-clinical-research-due-to-covid-19-equates-to-10-billion-potential-study-delays 2. Source: Tufts Center for the Study of Drug Development - Impact Report - Volume 22 Number 1-January/February 2020: https://static1.squarespace.com/static/5a9eb0c8e2ccd1158288d8dc/t/5e303c3dd4520c015cb8a4b1/1580219453985/Jan Feb2020_CropSummary.JPG 3. Source: Article from Nature - When will clinical trials finally reflect diversity? - 09 May 2018: https://www.nature.com/articles/d41586-018-05049-5 4. Source: Tufts Center for the Study of Drug Development - Impact Report - Volume 20 Number 3-May/June 2018 as it relates to non-orphan drugs: https://static1.squarespace.com/static/5a9eb0c8e2ccd1158288d8dc/t/5af455f9352f53cd2156399e/1525962233431/summary_mayjune 18.pdf%20 13#14Science 37 Pioneered Decentralized Clinical Trials. Patient Centric Model Generates Better Outcomes Patient Centric Model Unified platform Proven processes Differentiated Services ■ ■ Decentralized Clinical Trials Science 37 Pioneers Virtual Trials in 2014 7 Years of insights in DCT Source: Science 37 Internal case study, reports, and estimates Science 37 We've conducted more fully virtual trials. 95+ decentralized clinical trials (DCTs) 366,000+ engaged patients Patients Meta site Sponsor DIDI Science 37 Outcomes TECHNOLOGIES Enroll Patients Faster Up to 15x faster than sites in same study Retain Patients Longer Up to 28% longer than industry average Represent the Real Population Up to 3x Potential of >$54M Higher enrollment from diverse communities Pharma Gain in revenue 3 months average trial acceleration 14#15Our Vision To be the category-defining Operating System that powers every clinical trial. 15#16Full-Stack, E-2-E Technology & Network Enables Trial Orchestration. ●●●●● Science 37 Patient Communities Telemedicine Investigators Mobile Nurses Remote Coordinators Connected Devices ▪ Social media and association networks I Provider, pharmacy and payer networks ▪ FASTER PATIENT RECRUITMENT On-demand, experience rated ■ All therapeutic areas; any geography ▪ ACCESS TO ANY PATIENT, ANYWHERE Highly scalable ▪ Measurable utilization rates ▪ REPEATABLE PROCESSES 01011000111010011001011 On-demand, gig-economy motivated I Managed via one set of SOPs ▪ PATIENT-CENTRIC FOCUSED EXPERIENCE I 10101001100011100 0 0 01100011100 0 0010100110001101 0101100011101001100101¹ 001010011000 01011000111010011001011 010110001110100110 ■ Flexibility to integrate with virtually any device ▪ New clinical data (cardiac, activity, sleep, lung function, etc) ROBUST, REAL-TIME EVIDENCE GENERATION Science 37 TECHNOLOGIES Ⓡ Technology Platform 1001100011101001100101101010001010010011001011011000101 WORKFLOW ORCHESTRATION EVIDENCE GENERATION DATA HARMONIZATION 16#17Full-Stack, E-2-E Technology Platform. Patient Communities Remote Coordinators Science 37 DCT Operating System This material is confidential and proprietary to Science 37® and shall not be distributed, edited, or modified in any way without written consent from Science 37. Telemedicine Investigators Mobile Nurses B Connected Devices 17#18Full-Stack, E-2-E Technology Platform. Patient Communities Remote Coordinators Science 37 PATIENT EXPERIENCE PATIENT REPORTED Workflow Evidence Orchestration Generation COORDINATOR EXPERIENCE INTERNAL Data Harmonization EXTERNAL CLINICAL CONDUCT INVESTIGATOR EXPERIENCE NURSE EXPERIENCE This material is confidential and proprietary to Science 37® and shall not be distributed, edited, or modified in any way without written consent from Science 37. Telemedicine Investigators Mobile Nurses B Connected Devices 18#19Full-Stack, E-2-E Technology Platform. Patient Communities Remote Coordinators Science 37 Retention CRM Recruitment CRM PATIENT EXPERIENCE S37 Patient App Trial Landing Pages Patient Concierge Health Status Workflow Evidence Orchestration Generation Investigator Support COORDINATOR EXPERIENCE Mobile Nurse Mgmt PATIENT REPORTED Symptom Reporting Long-term Follow-up Logistics Mgmt QOL ePRO INTERNAL UAT Validation Rapid Trial Builder Post Marketing Safety Remote Monitoring Open APIs Lab Data Data Harmonization Obs RO Tokenization Longitudinal Data Aggregation Query Management Performance Analytics EXTERNAL ClinROS EDC Integrations CLINICAL CONDUCT Sleep Monitoring Lung Function eSource Telemedicine Remote eConsent MeGATOR EXPERIENCE Activity Monitor Cardiac Safety SAE/AE Tracking Data Review and Approval Scheduling Clinical Coordination NURSE EXPERIENCE Labs Data Collection IMP Mgmt This material is confidential and proprietary to Science 37® and shall not be distributed, edited, or modified in any way without written consent from Science 37. Telemedicine Investigators Mobile Nurses Connected Devices 19#20Creating Optimal Trial Orchestration. Science 37 Science A DECENTRALIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AN INVESTIGATIONAL DRUG IN METASTATIC NSCLC Science 37 needs participants for a new research study to look at the safety and potential effectiveness of the investigational medication on its ability to shrink tumors in certain patients with metastatic non-small cell lung cancer (NSCLC). B Help advance cancer research Email Let's get started Patient Communities m 10011101001100101101010001010010011010100 Science 37 TECHNOLOGIES DCT Operating System 20#21Creating Optimal Trial Orchestration. Science 37 TECHNOLOGIES DCT Operating System Science 37 Telemedicine Investigators 0 000111010011001011010100010100100110010100100 Science37 C demo.science37.com/welcome Apps Science 37 TLP 537 Platform Demo Notes M Email Calendar Science 37 Hi Matt Run Sheet Jira Tickets Product Tickets Home Salesforce Notifications Investigator Welcome to Science 37 02 Top Usability Matt Muman Investigator MM 21#22Creating Optimal Trial Orchestration. ← Science37 Apps Science 37 Science 37 Science 37 Univer... Science 37 stage.nora.science37.com/trials/28382/sites/4885/patients Back to my sites Patients Site Queries Site Reports Waiting for stage.nora.science37.com.... Science 37 My Patients My Patients Patients Filter All QStart typing here to search... с A * A Other Bookmarks FW Finn Willem Add Patient Show 100 Patient Communities Remote Coordinators m 10100110001110100 10 101001 10001110100110010110101009 Science 37 TECHNOLOGIES DCT Operating System 201110100110010110001 1111010011001011010100010101 Connected Devices Telemedicine Investigators Mobile Nurses 22#23Creating Optimal Trial Orchestration. Good evening, Danielle Tasks for today EQ-5D-5L Due Today Science 37 Modified Cancer Therapy Satisfaction Questionnaire Due Today NCI PRO-CTCAE ITEMS Due Today Daily IMP Compliance Tracking Due Today Next upcoming tasks Patient Communities emote hators 0 10011000110 10100110001110100170118 101001100011101001100101101000 Ⓡ Science 37 TECHNOLOGIES DCT Operating System 1001110100 1111101001 Connectel Devices demo.science37.com/trials/442/sites/37/patients/23690 Science 37TLPS 537 Platform Demo Notes Email Calendar + Run Sheet + Jira Tickets Product Tickets Home | Salesforce in Notifications Science 37 (Dashboard G Schedule Calendar Documents (1) Electronic Medical Records Photos (1) Telemedicine Investigators Contacts (4) A Subject ID: 7910110952 Danielle Smith Ongoing Scheduled Jan 11 ICF Forms Informed Consent Recurring Visit 1 Jan 11 Subject needs to complete task Medication Shipping Confirmation Nurse needs to complete task O Jan 11 Jan 18 Visit 3 Feb 10 Metastatic MSCLC. 02 Top Usability... Investigator Incognito (2) I Matt Munson-Investigator MM 23#24Creating Optimal Trial Orchestration. Science 37 Patient Communities Remote Coordinators 0 D 10100110001110100170710 10100110001110100110010110109000) Science 37 TECHNOLOGIES DCT Operating System ●●●●● 0 Top1110100110010110001 11100011010011001011010100010101 Connected Devices Telemedicine Investigators Mobile Nurses App Mon Mapaenas. Science 37 https://sandboxnora science37.com/trials funding Opportun Clinical Trials Trial # 9041929 CITY CENTER Trial name BO41929: ALPHA-T 4 Total Records: 1 d Disantos Learning Sponsor Roche Carol Hathaway 24#25DCT Configurations to Enable Any Study Full DCT Metasite TM Technology Technology Configurations Network Configurations Study Configurations Science 37 Science 37 Platform Patient Engagement Patient Recruitment Early Phase Remote eConsent Coordinator Network Pivotal Studies Trial Orchestration eSource (eCOA, eCRF) Mobile Nurse Network Long-Term Follow-up Telemedicine Investigator Network Real-World Evidence Sole Provider This material is confidential and proprietary to Science 37® and shall not be distributed, edited, or modified in any way without written consent from Science 37. 3rd-Party Integration Connected Devices Any Indications 25#26Science 37 is a Pioneer & Leader in DCT. Large Pharma Customers Mid-Size Pharma Customers Biotech Customers Academic/Gov't Customers Science 37 AMGEN PHARMACEUTICAL COMPANIES OF Janssen Johnson Johnson Incyte Adrenas a bridgebio company allo vir Boehringer Ingelheim BILL & MELINDA GATES MEDICAL RESEARCH INSTITUTE gsk Genentech Roche & NOVARTIS REGENERON freenome VectivBio ucb ARENA PHARMACEUTICALS H3 HARMONY BIOSCIENCES Duke Clinical Research Institute Voyager THERAPEUTICS NIH National Institutes of Health Turning Discovery Into Health ascendis pharma SANOFI USC Dermatology moderna advicenne QOL Medical FDA U.S. FOOD & DRUG ADMINISTRATION BioSpace Digital Health 150 Press & Awards CBINSIGHTS Forbes ADVARRA THE WALL STREET JOURNAL. FOUNDATION MEDICINEⓇ medgate_ Partnerships PPD v Syneos. Health AiCure® ERT This material is confidential and proprietary to Science 37® and shall not be distributed, edited, or modified in any way without written consent from Science 37. BUSINESS INSIDER TL TechCrunch FORTUNE FIERCE Biotech DATAVANT II Hillrom.M SIGNANT HEALTH Xperiome 26#27Customer Success Stories. Decentralization on Massive Scale. Oncology Diagnostic Pivotal Trial Situation • Rescued top-CRO traditional brick & mortar study with enrollment challenges 5,380+ enrolled in just half of the total recruitment period. Science 37 Approach . Patient enrollment Phlebotomist visit Follow-up after colonoscopy ● ● Outcomes ..... 2,000+ Enrolled in a month Faster Start-up and Greater Continuity of Care. Breast Cancer Study Situation Needed a means to continue intravenous treatments for cancer study 4x faster study start-up Approach . Enrolled at site • Telemedicine visit ● Outcomes Chemotherapy delivered in- home by mobile nurse All clinical trials are special but this one... is above and beyond anything I have seen in my oncology career. » Executive Group Medical Director Top 10 Pharma Company 27#28Why Science 37 Wins¹. Tech is not in our competitors' DNA • DCT model requires different SOPS DCT would cannibalize competitors' core business Complete TRIAL ORCHESTRATION None ● Science 37 CROS parexel. ICON Syneos. Health COVANCE. PRANEALTHSCIENCES Clinical Home Health medix It's a matter of life pcm healthcare MAKING CHANGE HAPPEN IQVIA ELLIGO HEALTH RESEARCH CLINICAL FIRMA CLINICAL RESEARCH m Site-Based Recruitment Patient Recruitment langland Trial m Health, Teams PPD Site-Centric 1. Science 37 management team assessment based on competitor public announcements. antidote /// trialbee TrialSpark wcg IBM Watson Health. medrio ORACLE Little to minimal ability to orchestrate User Experience (UX) not informed by their own users eClinical Providers yprime TECHNOLOGY Science 37 TECHNOLOGIES The Clinical Trial Operating System Ⓡ SIGNANT HEALTH Clinical Ink:medidata Confident Decisions, Faster ERT Veeva Decentralization Tech THREAD This material is confidential and proprietary to Science 37® and shall not be distributed, edited, or modified in any way without written consent from Science 37. MEDABLE Fully Decentralized 28#29Why Science 37 Wins in the Future. Complete Science 37 TRIAL ORCHESTRATION None CROS parexel. OCON PRAHEALTHSCIENCES medix It's a matter of life COVANCE. Clinical Home Health pcm healthcare MAKING CHANGE HAPPEN Site-Centric Syneos. Health ELLIGO HEALTH RESEARCH CIRCUIT CLINICAL IQVIA FIRMA CLINICAL RESEARCH v mm Site-Based Recruitment Patient Recruitment langland antidote /// Trialx trialbee TrialSpark Health, Teams 1. Science 37 management team assessment based on competitor public announcements. PPD ▪ The CRO Clinical Trial Operating System (OS) ● wcg ORACLE yprime ● TECHNOLOGY ● IBM Watson Health. medrio Science 37 TECHNOLOGIES C eClinical Providers The Clinical Trial Operating System Continue to extend E2E, OS of the future Partnering with key point solutions Own tech workflow experience as competitive moat Ⓡ SIGNANT HEALTH Clinical Ink medidata Confident Decisions, Faster ERT Veeva Decentralization Tech THREAD This material is confidential and proprietary to Science 37® and shall not be distributed, edited, or modified in any way without written consent from Science 37. MEDABLE Fully Decentralized 29#30Science 37 Defines the Standard Clinical Trial OS. Empowers Clinical Trials and Optimizes the Experience & Outcomes for Participants Traditional, site-based trial Sponsor Site Contract Research Associates Study Coordinator Investigator Nurse Patients Science 37 of DIDI co +Decentralized trial (DCT) Patients Metasite Sponsor DIDI Home Telemedicine Patients Providers 100 DIDI Sponsors Future Clinical Trials ⠀⠀⠀⠀ PoC Site To win in this new era, leaders will need the following: Ability to activate any Provider and any Patient - regardless of premises A network of traditional providers, telemedicine providers, mobile nurses and remote coordinators A flexible operating system to seamlessly navigate between on-site and off-site 30#31Large Market Opportunity. 2021 Total Available Market (TAM) ~ $195 Billion R&D Spend Annual growth in R&D spend Global pharma R&D spend ($B) 136 139 11 2012 145 149 Science 37 2013 2014 2015 159 168 1. Pre-COVID forecast. Source: Evaluate Pharma: BCG Analysis 2. Serviceable Available Market: Management estimates as of April 2021 181 186 188 4-5% 195 Forecast¹ 202 211 221 2016 2017 2018 2019 2020F 2021F 2022F 2023F 2024F R&D Spend: 2012 - 2019 R&D Spend: 2020-2024 2021F Serviceable Available Market (SAM) ■CRO 33% 50% $60 Billion CAGR ~6% '21 - ¹26 17% ■ Home Health ■ Recruitment & eClinical 31#32Science 37 Growth Drivers. 01 Core ■ SaaS and aPaaS ■ Patient Platform (Recruitment, Enrollment, & Engagement) ▪ Globalization of Metasite ■ Connected Devices at Scale Expanded Commercial Presence H 02 Expand ▪ CRO ▪ ECOA ▪ RWE ▪ Clinical Care Diversity 1. Serviceable Available Market: Management estimates as of April 2021 Science 37 01 02 03 03 Extend ▪ Provider Tech Enablement Provider Network Sources Performance & Risk Mgmt. ■ ■ Disrupting a $60b¹ Market Constructing the category-defining Clinical Trial Operating System 32#33Millions ($) Top-Line Growth Acceleration. $300 $250 $200 $150 $100 $50 $61 Q1-2020 Science 37 Qualified Funnel Over Time $144 Q2-2020 $175 Q3-2020 $175 $248 4x Growth Y/Y Q4-2020 Q1-2021 Millions ($) $120 $100 $80 $60 $40 $20 TTM Gross and Net Bookings $14 $13.9 Q1'20 Net Bookings Gross Bookings $33.1 $32.9 Q2 '20 $45.1 $41.7 Q3-20 $61.2 $55.7 $102.7 Q4-20 $95.4 Q1-21* *Q1-2021 Preliminary Bookings 33#34Representative Bookings in Past 12 Months. Science 37 Biotech Top 5 pharma Top 5 Pharma Biotech Biotech Government Biotech Top 5 pharma Biotech Biotech Biotech Top 5 pharma Biotech Biotech Biotech Value 1 lo T atyb in Indication $4.1M Infectious Disease $5.1M Respiratory $2.2M Neurology $1.4M Gastrointestinal $1.1M Huntington's $22.6M COVID $18.5M Oncology $6.3M Nephrology $2.7M Nephrology $1.4M Adrenal Hyperplasia $1.5M CSID $4.8M Oncology $3.8M FNAD $1.5M CSID $0.8M Respiratory Phase ||| || || || ||| ||| ||| || IV || || IV IV First Patient Apr 2021 May 2021 Apr 2021 Jan 2021 Apr 2021 Apr 2021 Jul 2020 May 2021 May 2021 Mar 2021 Jul 2021 Nov 2020 Jul 2021 Jul 2021 May 2021 Contract 18 Months 39 Months 9 Months 24 Months 38 Months 36 Months 12 Months 21 Months 8 Months 12 Months 19 Months 36 Months 8 Months 19 Months 8 Months M Tech+ Metasite Full DCT Global 34#35Top-Line Acceleration. Average Contract Value Millions ($) $3.0 $2.0 $1.0 12 8 4 0 $1.4 Q1 2020 Science 37 2 Q1 2020 Net Promoter Score (NPS): $1.9 Q2 2020 a Q2 2020 $2.1 Q3 2020 Net New Logos 3 Q3 2020 Science 37 NPS 2 $1.8 $2.5 79% Growth Q1 '20 vs. Q1 '21 Q4 2020 Q4 2020 Q1 2021 27 New Logos in 2020 7 40 1. Source: Science 37 Net Promoter Score Survey - Q4 2020 based on a limited number of survey responses 2. Based on Request for Proposals (RFPs) sent Q1 2021 Millions ($) $500 $400 $300 $200 $100 $12 2019 $56 2020 Net Bookings thru 2025 $119 2021F $218 2022F $258 $338 2023F 52% CAGR '20-'25 $444 2024F 2025F 35#36Millions ($) Income Statement. $400 $350 $300 $250 $200 $150 $100 $24 $0 '20'22 CAGR: 108% 2020 1 Significant Revenue Scaling Science 37 $52 2021F 1. 2020 Figures are unaudited 2. As of April 12, 2021 3. Gross Margin excludes stock-based comp $182 $102 '20-'25 F CAGR 73% $261 81% 2 Revenue Coverage in '21F 2022 F 2023 F 2024F $362 2025 F Millions ($) $200 $150 $100 $50 $0 4.7% $1.1 2020 1 Gross Margin Expansion 31.6% $16.5 2021 F 45.9% $47.0 3 2022 F 50.0% $91.3 53.8% $140.7 54.5% 2024 F $197.7 55% Gross margin in '25F 2023 F 2025 F 36 60% 50% 40% 30% 20% 10% 0%#37Income Statement. In 000's Revenue Total Revenues Y-o-Y Growth Cost of Revenues Gross Profit Gross Margin % General and Adminstrative (ex. Dep/Amort & Stock- based Comp) Adjusted EBITDA Adj. EBITDA Margin % 2019 Actuals Science 37 $14,081 N/A 7,852 $6,229 44% 21,620 ($15,391) -109% 2020 Actuals $23,704 68% 22,597 $1,107 5% 28,157 ($27,050) -114% 2021 Forecast $52,130 120% 35,658 $16,472 32% 65,053 ($48,580) -93% 2022 Forecast $102,253 96% 55,271 $46,982 46% 93,906 ($46,924) -46% 2023 Forecast $182,497 78% 91,208 $91,289 50% 106,688 ($15,399) -8% 2024 Forecast $261,319 43% 120,602 $140,718 54% 125,768 $14,949 6% Adjusted EBITDA is defined as net income, adjusted for: income taxes, depreciation and amortization, interest expense (net), stock-based compensation, other expense/(income), net, restructuring and related charges, and costs associated with this contemplated transaction. 2025 Forecast $362,420 39% 164,690 $197,730 55% 143,031 $54,699 15% 37#38Comparable Company Benchmarking. Drug Development Technology Disruptive Healthcare Technology Platforms Vertical Software Revenue CAGR 2021-2023 Enterprise Value / 2023E Revenue 100% 80% 60% 40% 20% 0% 25.0x 20.0x 15.0x 10.0x 5.0x 0.0x 14% CERT 5.8x S37 Source: Company internal data, public filings, and CapitaliQ as of 5/6/21. Science 37 20% SLP 11.7x CERT 26% 14.8x MX CT HCAT SLP mul.…..... 10% 10% TDOC GDRX BFLY BSY GWRE 20% 19.7x MX CT 24% PHR 6.6x 27% 7.4x HCAT TDOC 36% 8.9x 74% PHR 9.7x GDRX 12.8x I BFLY 8.1x TYL 13% TYL 8.4x GWRE 17% DCT 12.3x BSY 20% 25% VEEV NCNO 17.0x 13.3x il DCT 87% S37 17.9x NCNO VEEV#39Selected Comparable Companies. Disruptive Healthcare Technology Platforms Drug Discovery Enablement Vertical Software Science 37 Butterfly Network Science 37 HealthCatalyst M MaxCyte® CERTARA Duck Creek Technologies Bentley TM GGUIDEWIRE tyler 000 (a) Figures presented are the mean for each category. Source: Company internal data, public filings, and CapitaliQ as of 5/6/21. Phreesia technologies GoodPx O TELADOC. S+ Simulations Plus SCIENCE+ SOFTWARE SUCCESS incino. Veeva EV/Revenue Revenue CAGR 2023E (a) 2021-2023E (a) 9.1x 15.4x 12.6x 5.8x 36% 20% 16% 87%#40Science 37 Investment Highlights. Disrupting the $60b Clinical Trial Industry Science 37 $3 § X X 1 ■ ■ ■ Category-Defining Clinical Trial Operating System Unifying technology platform to enable workflow, evidence generation and data harmonization On-demand telemedicine investigators and gig-economy nursing for home visits Integrations into networks (EHR and EDC) and connected devices to expedite trial operations Strong Financial Performance $444M net bookings in 2025 expected to increase from $119M in 2021 $362M revenue in 2025 expected to increase from $52M in 2021 Gross profit margin expected to increase to 55% in 2025 I I ■ ■ ■ ■ Significant Growth Opportunities Ahead Model expansion: commercial, geographic, technology Expanded offerings: rapidly growing adjacencies Potential M&A opportunities Up to 15x faster than traditional clinical trials Up to 28x greater patient/participant retention Up to 3x more diverse participants ■ 40